News | June 30, 2022
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
The settlement and dismissal resolves all claims between the parties
The settlement and dismissal resolves all claims between the parties
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
First and only PARP inhibitor to improve invasive disease-free survival in patients
73% have cited fears like losing eyesight, painful procedure or long recovery period when it comes to cataract surgeries
Silo enters into commercial evaluation license agreement for next generation liposomes
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Subscribe To Our Newsletter & Stay Updated
